Unprovoked seizures, also known as primary generalized seizures, are seizures that occur without any apparent cause or trigger. They are the most common type of seizure in adults and can occur either as a single episode or as recurring episodes. Seizures occur when there is an abnormal electrical activity in the brain produced by clusters of neurons that are suddenly activated simultaneously. Unprovoked seizures may last anywhere from a few seconds to several minutes, and can include a variety of symptoms such as loss of consciousness, twitching or jerking movements, uncontrolled electrical activity, changes in behavior and alertness, or even temporary confusion. While there is no single cause of unprovoked seizures, some factors have been identified, including structural brain lesions, drug or alcohol abuse, head injury, underlying medical conditions, genetic factors, and stress or lack of sleep. Depending on the type of seizure experienced and the underlying cause, treatment for unprovoked seizures may include medications, surgery, or lifestyle modifications. Medications, such as anti-seizure medications, are used to help suppress seizure activity and to help prevent future seizures. Other treatments, such as transcranial magnetic stimulation and vagus nerve stimulation, may be used to help reduce the frequency of seizures or to help people with epilepsy gain better control over their seizures. It's important for individuals who experience unprovoked seizures to work with their healthcare provider to identify the underlying cause and determine the best course of treatment. With proper diagnosis and treatment, individuals can often manage their seizures and lead a normal life.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States